Evidence map›Paper›PMID 39075850›Full record

ArticleThoracic cancer2024

Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.

Kosei Doshita, Tateaki Naito, Suguru Matsuda, Meiko Morita, Motoki Sekikawa, Keita Miura, Hiroaki Kodama, Michitoshi Yabe, Noboru Morikawa, Yuko Iida and 8 more

Abstract read
In one paragraph

Article in Thoracic cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Prognostic impact of weight loss during first-line chemotherapy in extensive-disease small cell lung cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kosei DoshitaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0000-0002-0475-573X
Tateaki NaitoDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0000-0003-4047-2929
Suguru MatsudaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Meiko MoritaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0009-0000-9248-4265
Motoki SekikawaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0009-0005-5637-5199
Keita MiuraDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Hiroaki KodamaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0000-0002-0953-3183
Michitoshi YabeDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Noboru MorikawaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Yuko IidaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0000-0002-1807-7781
Nobuaki MamesayaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Haruki KobayashiDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Ryo KoDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Kazushige WakudaDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Akira OnoDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Haruyasu MurakamiDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0000-0003-2416-546X
Hirotsugu KenmotsuDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Toshiaki TakahashiDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0000-0002-8188-2505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy-induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy-induced anorexia and weight loss during platinum-based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy-induced anorexia and therapeutic outcomes in patients with stage IV non-small-cell lung cancer undergoing platinum-based chemotherapy combined with immune checkpoint inhibitors.

methodsThe study retrospectively reviewed the medical records of 106 patients with stage IV non-small-cell lung cancer treated with platinum-based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy-induced anorexia group. Chemotherapy-induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression-free and overall survival were used to measure treatment efficacy.

resultsChemotherapy-induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non-chemotherapy-induced anorexia group. Progression-free and overall survival were shorter in the chemotherapy-induced anorexia group than in the non-chemotherapy-induced anorexia group, but the difference was not statistically significant.

conclusionsChemotherapy-induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non-small-cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy-induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum-based chemotherapy combined with immune checkpoint inhibitors.

Indexed as

AnorexiaLung NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedRetrospective StudiesTreatment OutcomeImmune Checkpoint Inhibitorsanorexiachemotherapyimmune checkpoint inhibitorsnon‐small cell lung cancertreatment efficacy

Identifiers

PMID39075850
PMCPMC11367660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.